45 reports

  • 6.1 INTRODUCTION
  • FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2016-2023 (USD MILLION)

PREBIOTICS RESIST GASTRIC ACIDITY AND HYDROLYSIS CAUSED BY ENZYMES AND GASTROINTESTINAL ABSORPTION.

  • Depression
  • Mineral Supplement
  • Market Size
  • Arla Foods
  • Cargill Inc.

One of the major reasons for the high bioavailability of organic minerals is that, unlike inorganic minerals, these do not interact with fiber, tannin, phytate, silicates, oxalate, or other minerals in the gastrointestinal tract.

  • Mineral Supplement
  • Pig
  • World
  • Alltech Inc.
  • Kemin Industries, Inc.

THE MICROPEARLS SPRAY FREEZING TECHNOLOGY ALLOWS FOR THE TIMELY RELEASE OF THESE ## KEY NUTRIENTS THROUGHOUT AN ANIMAL' S GASTROINTESTINAL TRACT.

  • Mineral Supplement
  • North America
  • United States
  • World
  • Market Size
  • VITAMIN & MINERAL PREMIXES MARKET, BY FUNCTIONALITY

Q. ##.

  • Mineral Supplement
  • World
  • Market Size
  • Glanbia plc
  • Nutreco N.V.

MARKET ##.

  • Mineral Supplement
  • APAC
  • Japan
  • World
  • Demand

You can easily book an appointment with one online.

  • Mineral Supplement
  • World
  • Market Size
  • Alltech Inc.
  • Kemin Industries, Inc.

The company is one of the key players inn pharmaceuticals and consists of Employees: ## Company Type: Public Ticker Symbol : TYO:## Year of Incorporation : ## Product Categories: Gastrointestinal Oncology Central Nervous System Cardiovascular & Metabolic Industry: Pharma

  • Depression
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Mineral Supplement
  • China
  • Demand
  • Amway Corporation
  • Joincare Pharmaceutical Group Industry Co., Ltd.

You can easily book an appointment with one online.

  • Depression
  • Mineral Supplement
  • Allergan plc
  • Eli Lilly & Co.
  • Pfizer Inc.

These medicines are generally prescribed unless one has tried an SSRI first without improvement.

  • Depression
  • World
  • AstraZeneca PLC
  • Lundbeck Inc.
  • Pfizer Inc.

AD is one of the most common types of NDDs.

  • Depression
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Energy
  • Mineral Supplement
  • Vitamin
  • China
  • Demand

It is estimated that worldwide one in five men and one in three women are at risk of an osteoporotic fracture.

  • Mineral Supplement
  • World
  • Forecast
  • Quidel Corporation
  • Roche Group

Research; ##(##-##): ##-##.

  • Depression
  • Mineral Supplement
  • Alkermes plc
  • Allergan plc
  • Otsuka Pharmaceutical Co., Ltd.

The subsidiary is focused on aging care, critical care & surgery, gastrointestinal function, and pediatrics.

  • Depression
  • Mineral Supplement
  • North America
  • United States
  • Demand

The magnitude of the impact has been categorized as described below: ## ## ## ## ## ## ## ## ## ## Low High High Low Low ## ## ## ## ## High High ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Promising drug pipeline Changes in lifestyle Low ## ## ## ## ## High Low

  • Depression
  • Actavis plc
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • GlaxoSmithKline plc

Q. ##.

  • Mineral Supplement
  • United States
  • Cargill Inc.
  • Koninklijke DSM N.V.
  • Nutreco N.V.

In addition, we expect one of our principal collaborators, the U. S.

  • Depression
  • Healthcare
  • Therapy
  • United States
  • VistaGen Therapeutics, Inc.

MAR ##, 2015: SUVEN LIFE SECURES ONE (##) PRODUCT PATENT EACH IN EURASIA AND ISRAEL The U. S.

  • Depression
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Depression
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Depression
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Depression
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd
  • JNJ-18038683 - Drug Profile
  • JNJ-18038683 - Drug Profile

One analysis demonstrated that lurasidone has early separation from placebo by Week ## and that the ## mg dosage may provide significant additional efficacy benefit.

  • Depression
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • JNJ-18038683 - Drug Profile
  • JNJ-18038683 - Drug Profile

The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are ##, ##, ## and ## respectively.

  • Depression
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Depression affects an estimated one in ## adults (##. ##%) per year and one in six people (##. ##%) will experience depression at some time in their life.

  • Depression
  • North America
  • United States
  • World
  • Demand

Study ##B - Patients with severe PPD (n=##): Patients were randomized to one of three treatment groups (brexanolone ## g/ kg/ hour, brexanolone ## g/ kg/ hour, or placebo) on a ##:##:## basis.

  • Depression
  • Therapy
  • United States
  • Company Operations
  • SAGE Therapeutics
  • DEPRESSION - PIPELINE BY LIXTE BIOTECHNOLOGY HOLDINGS INC, H1 2018
  • DEPRESSION - PIPELINE BY OTSUKA HOLDINGS CO LTD, H1 2018

No deaths, cardiovascular events or gastrointestinal perforations occurred.

  • Depression
  • Mental Health
  • Mineral Supplement
  • United States
  • Anavex Life Sciences Corp.

The prominent features of this report are - ##.

  • Cardiology
  • Mineral Supplement
  • Therapy
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Depression
  • Mineral Supplement
  • World
  • Product Initiative
  • RespireRx Pharmaceuticals Inc.

(NYSE: GI), WHICH OFFERS PHYSICIANS A BROAD PORTFOLIO OF PRODUCTS TO TREAT GASTROINTESTINAL CONDITIONS, FOR APPROXIMATELY $## MILLION.

  • Clinical Trial
  • Depression
  • Mental Health
  • Therapy
  • GlobalData's company